

**Advanta Analytical Laboratories**10935 CR 159 Tyler, TX 75703  
Phone: (903) 805-9955 Fax: (903) 839-2494  
www.aalabs.com

CLIA: 45D2063134

CAP: 8863194

Laboratory Director: Mary Long, Ph.D., NRCC

**Patient:** Race Bannon  
**DOB:** 02-05-1960  
**Gender:** Male**Accession:** 772182  
**Specimen:** Urine  
**Provider:** Doe, John**Client:** Demo Account  
**Collected Date:** 04-22-2022  
**Report Date:** 04-26-2022**Advantage Urine Culture Panel**  
**FINAL RESULT****Proteus mirabilis**

04-26-2022 02:16 PM &lt; 10,000 cfu/ml

Sensitivities	MIC µg/mL	Interpretation
Amikacin	≤8	S
Ampicillin	≤8	S
Ampicillin/Sulbactam	≤4	S
Aztreonam	≤1	S
Cefazolin	4	S
Ceftazidime	≤1	S
Ceftriaxone	≤0.5	S
Ciprofloxacin	≤0.5	S
Doripenem	≤0.5	S
Ertapenem	≤0.25	S
Gentamicin	≤2	S
Imipenem	≤0.5	S
Levofloxacin	≤1	S
Meropenem	≤0.5	S
Minocycline	>8	R
Nitrofurantoin	>64	R
Piperacillin	≤16	S
Tetracycline	>8	R
Ticarcillin/Clavulanic Acid	≤8	S
Tobramycin	≤2	S
Trimethoprim/Sulfamethoxazole	≤2	S

R = RESISTANT

S = SENSITIVE

I = INTERMEDIATE

NI = NO INTERPRETATION

SD = Susceptible Dose Dependent

**THE HUMAN ADVANTAGE**

IN LABORATORY TESTING

Accession #772182

Patient Race Bannon

DOB 02-05-1960

Urine Culture Panel FINAL RESULT

Page 1 of 3



**Advanta Analytical Laboratories**

10935 CR 159 Tyler, TX 75703  
Phone: (903) 805-9955 Fax: (903) 839-2494  
www.aalabs.com

CLIA: 45D2063134

CAP: 8863194

Laboratory Director: Mary Long, Ph.D., NRCC

**Proteus penneri**

04-26-2022 02:16 PM 10,000-100,000 cfu/ml

Sensitivities	MIC µg/mL	Interpretation
Amikacin	≤8	S
Ampicillin/Sulbactam	≤4	S
Aztreonam	≤1	S
Ceftazidime	≤1	S
Ceftriaxone	≤0.5	S
Ciprofloxacin	≤0.5	S
Doripenem	≤0.5	S
Ertapenem	≤0.25	S
Gentamicin	≤2	S
Imipenem	≤0.5	S
Levofloxacin	≤1	S
Meropenem	≤0.5	S
Minocycline	>8	R
Piperacillin	≤16	S
Tetracycline	>8	R
Ticarcillin/Clavulanic Acid	≤8	S
Tobramycin	≤2	S
Trimethoprim/Sulfamethoxazole	≤2	S

R = RESISTANT

S = SENSITIVE

I = INTERMEDIATE

NI = NO INTERPRETATION

SD = Susceptible Dose Dependent

**THE HUMAN ADVANTAGE**

IN LABORATORY TESTING

Accession #772182

Patient Race Bannon DOB 02-05-1960

Urine Culture Panel FINAL RESULT

Page 2 of 3



**Advanta Analytical Laboratories**

10935 CR 159 Tyler, TX 75703  
 Phone: (903) 805-9955 Fax: (903) 839-2494  
 www.aalabs.com

CLIA: 45D2063134

CAP: 8863194

Laboratory Director: Mary Long, Ph.D., NRCC

**Proteus species**

04-26-2022 02:16 PM >100,000 cfu/ml

Sensitivities	MIC µg/mL	Interpretation
Amikacin	≤8	S
Ampicillin	≤8	S
Ampicillin/Sulbactam	≤4	S
Aztreonam	≤1	S
Cefazolin	4	I
Ceftazidime	≤1	S
Ceftriaxone	≤0.5	S
Ciprofloxacin	≤0.5	S
Doripenem	≤0.5	S
Ertapenem	≤0.25	S
Gentamicin	≤2	S
Imipenem	≤0.5	S
Levofloxacin	≤1	S
Meropenem	≤0.5	S
Minocycline	>8	R
Nitrofurantoin	>64	R
Piperacillin	≤16	S
Tetracycline	>8	R
Ticarcillin/Clavulanic Acid	≤8	S
Tobramycin	≤2	S
Trimethoprim/Sulfamethoxazole	≤2	S

R = RESISTANT

S = SENSITIVE

I = INTERMEDIATE

NI = NO INTERPRETATION

SD = Susceptible Dose Dependent

**THE HUMAN ADVANTAGE**

IN LABORATORY TESTING

Accession #772182

Patient Race Bannon

DOB 02-05-1960

Urine Culture Panel

FINAL RESULT

Page 3 of 3